Mihai Turcu-Stiolica

Mr. Mihai Turcu-Stiolica

Rheumatology, University of Medicine and Pharmacy of Craiova, Craiova, Dolj, Romania
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RURoxana Doina Ungureanu
Roxana Doina Ungureanu
CBCristina Elena Bita
Cristina Elena Bita
NVNicoleta Mirela Voicu
Nicoleta Mirela Voicu
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
SFSineta Cristina Firulescu
Sineta Cristina Firulescu
FVFlorentin Ananu Vreju
Florentin Ananu Vreju
Background/Objectives: Spondylarthritis (SA) is characterized by high clinical heterogeneity, often resulting in a discrepancy between systemic inflammation and patient-reported symptoms. While hematologic indices are emerging as cost-effective biomarkers, their role in phenotypic differentiation remains unclear. We investigated the utility of traditional inflammatory markers, including the novel fibrinogen-to-platelet ratio (FPR), in differentiating SA subtypes and predicting patient-reported disease activity. Methods: This cross-sectional study included 64 patients with spondylarthritis: axial SA (n = 32), peripheral SA (n = 8), and psoriatic SA (n = 24). Clinical assessments included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Functional Index (BASFI). Systemic inflammation was evaluated via C-reactive protein (CRP), fibrinogen, and calculated ratios (NLR, PLR, MLR, and FPR). Principal Component Analysis (PCA) was employed to map the inflammatory architecture, while Receiver Operating Characteristic (ROC) curves evaluated the predictive power for high disease activity (BASDAI ≥ 4). Results: Significant phenotypic differences were observed with the FPR demonstrating superior discriminative capacity (p = 0.003). Patients with peripheral SA exhibited significantly higher FPR (median 1.88) compared to axial (1.33) and psoriatic (1.32) subtypes, and the dedicated ROC analysis for phenotypic discrimination yielded an AUC of 0.866 (95% CI: 0.745–0.987) (1.36, p = 0.039). HLA-B27 prevalence was low overall (31.3%) and in psoriatic SA (4.2%, p = 0.012). Correlation analysis revealed strong associations between BASDAI and BASFI (ρ = 0.79), NLR and MLR (ρ = 0.78), and CRP and fibrinogen (ρ = 0.66). PCA identified two independent inflammatory dimensions explaining 74.8% of variance: neutrophil-hypercoagulable axis (41.4%, driven by NLR, PLR, and MLR), and an acute-phase/fibrinogen axis (33.4%, driven by CRP, fibrinogen, and FPR). Notably, FPR clustered with acute-phase reactants rather than leukocyte-derived ratios, supporting its role as a marker of systemic inflammatory burden. Although fibrinogen is involved in the coagulation cascade, the absence of direct coagulation markers precludes definitive characterization of this component as hypercoagulable. ROC analysis revealed that fibrinogen showed the highest discriminative ability for disease activity (BASDAI ≥ 4), with an AUC of 0.690 (95% CI: 0.519–0.861), followed by NLR (0.621), MLR (0.592), and FPR (0.583). However, overall discriminative performance remained modest, with most 95% confidence intervals crossing 0.5. Conclusions: FPR emerges as a robust phenotypic biomarker capable of discriminating against SA subtypes, particularly identifying peripheral SA with high accuracy and excellent negative predictive value. In contrast, its ability to predict patient-reported disease activity remains limited, reinforcing the distinction between trait and state biomarkers. Exploratory PCA revealed that FPR clusters with acute-phase reactants rather than leukocyte-derived ratios, supporting its biological link to systemic inflammatory burden. These findings advocate for a dual-purpose biomarker approach in SA: FPR for phenotypic stratification and fibrinogen for activity assessment, while clinical indices remain indispensable for symptom monitoring. Validation in larger, prospective cohorts is warranted.

30 June 2021
Verified
Journal Article
Open access
MVMirela Nicoleta Voicu
Mirela Nicoleta Voicu
AAAna Maria Ahmet
Ana Maria Ahmet
Mihai Turcu-StiolicaMihai Turcu-Stiolica
Mihai Turcu-Stiolica
ATAdina Turcu-Stiolica
Adina Turcu-Stiolica
ABAndreea Lili Bǎrbulescu
Andreea Lili Bǎrbulescu
FPFlorica Popescu
Florica Popescu
The use of antibiotics represents a major health problem worldwide because they are often administered without medical prescription. This has led to different situations starting from a large use in inappropriate cases without medical recommendation, to a major issue that represents antimicrobial resistance. Our aim was to identify the opinion of healthcare workers (physicians and pharmacists) about the most effective solution at reducing antimicrobial resistance, helping the policy makers to take a decision. The present study was conducted from March 15th, 2021 to April 15th, 2021, using a virtual questionnaire. A total of 397 respondents provided a complete response to our questionnaire: 313 physicians and 84 pharmacists. Our results provided valuable insights that can be used to inform the development of a national health policy, resulting in population health gains. Our work provided an indication of physicians’ preferences toward solutions as “A tax on antibiotic consumption, which could be used to fund innovation strategies.” (41.53%) and “An educational program for patients that highlights the causes and effects of antimicrobial resistance.” (42.49%). The pharmacists preferred the solutions as “An educational program for patients that highlights the causes and effects of antimicrobial resistance.” (52.38%) and “Elimination of antibiotics from the list of the emergency pharmaceutical services.” (42.86%). A small number of physicians (2.24%) and pharmacists (3.57%) recommended as the most effective solution at reducing antimicrobial resistance “Restrain antibiotic use in the food industry.”

25 June 2022 in Value in Health
Verified
Journal Article
Closed access
ATA Turcu-Stiolica
A Turcu-Stiolica
SUSubtirelu
Subtirelu
MBM Bogdan
M Bogdan
VDVc Dinescu
Vc Dinescu
VGV Gheorman
V Gheorman
CLCv Lungulescu
Cv Lungulescu

1 May 2020 in Value in Health
Verified
Journal Article
Closed access
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
MSM.S. Subtirelu
M.S. Subtirelu
Mihai Turcu-StiolicaMihai Turcu-Stiolica
Mihai Turcu-Stiolica

10 June 2023 in Value in Health
Verified
Journal Article
Closed access
MSM.S. Subtirelu
M.S. Subtirelu
CNC.A. Nicola
C.A. Nicola
Mihai Turcu-StiolicaMihai Turcu-Stiolica
Mihai Turcu-Stiolica
ATA. Turcu-Stiolica
A. Turcu-Stiolica

Verified
Journal Article
Open access
PDF file
LȘLarisa Ionela Șuiu
Larisa Ionela Șuiu
FVFlorentin Ananu Vreju
Florentin Ananu Vreju
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
LSLoredana Elena Stoica
Loredana Elena Stoica
Mihai Turcu-StiolicaMihai Turcu-Stiolica
Mihai Turcu-Stiolica
PCPaulina Lucia Ciurea
Paulina Lucia Ciurea
Background/Objective: Psoriasis is a systemic inflammatory disease often associated with metabolic comorbidities, including hyperuricemia. While biological therapies effectively target inflammatory pathways, their specific impact on serum uric acid (SUA) levels remains debated. This study aimed to evaluate whether biological therapy, while reducing systemic inflammation, influences SUA levels in patients with moderate-to-severe plaque psoriasis. Methods: A prospective longitudinal cohort study was conducted involving 30 patients with moderate-to-severe plaque psoriasis. Patients received biological treatment (adalimumab, secukinumab or ustekinumab) and tsDMARDS (apremilast). Clinical severity was assessed using the Psoriasis Area and Severity Index (PASI). C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), SUA levels and other laboratory markers were measured at baseline and after 48 weeks of therapy. Results: Biological therapy led to a significant reduction in PASI scores (from 21.6 ± 10.7 at baseline to 0.4 ± 0.86 after 48 weeks of therapy, p < 0.001), and CRP decreased from a median of 5.75 mg/L at baseline to 3.55 mg/L, p < 0.001. ESR also declined from 26.2 ± 11.4 mm/h to 19.0 ± 8.06 mm/h, p < 0.001. However, no statistically significant change was observed in mean SUA levels 5.49 ± 1.55 vs. 5.55 ± 1.60 mg/dL; p = 0.758. Subgroup analysis revealed that SUA levels remained stable regardless of the specific biological agent used or the degree of clinical improvement. Conclusions: Our findings suggest that while biological therapy is highly effective in controlling skin and systemic inflammation in psoriasis, it does not modify SUA levels. These results imply that hyperuricemia in psoriasis may be driven by metabolic factors independent of the primary inflammatory pathways targeted by current biologics.